AbTis is a bio-technology company which is specialized in antibody-drug conjugates (ADC) linker platform with its own proprietary technology. We are developing the 3rd generation of ADCs to improve outcomes for cancer patients with pipelines designed to enhance the safety and efficacy of the current ADCs by applying AbTis’ linker platform, AbClick®. This technology is applicable to 'off-the-shelf' antibodies without any modification as well as it can be conjugated site-selectively to antibodies. AbTis aims to develop innovative pipelines to create positive economic impact and long-term value, improved quality of life for the patients worldwide.

AbClick® : AbTis cyclic peptide (AbClick®) tightly binds to the IgG Fc domain. K248 ε-amine and the carbonyl group in AbClick® are in a proximity to undergo an amide bond formation reaction. The site selectivity depends on the reactivity of carbonyl group: react with amine mainly in a pseudo first order type. AbClick® has two different types of technologies: AbClick® Standard & AbClick® Pro. AbClick® Standard reduces the FcRn binding affinity, which can decrease the half-life of the antibody, while AbClick® Pro allows to maintain the inherent half-life of the antibody. By adjusting the half-life of the antibody, AbClick® Standard can be used for companion diagnostics of tumor and RIT(radio-immunotherapy) due to short half-life whereas AbClick® Pro is applicable to treat solid tumors due to its long half-life.

Private

Biotech, R&D Service